Skip to main content

Table 6 Rocket-AF study: primary safety outcomes

From: Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective

Outcomes Rivaroxaban Warfarin P NNT/NNH
Major and non-major clinically relevant 14.91 14.52 0.442 333
≥2 g/dL Hb drop 3.60 3.45 0.576 667
Transfusion (>2 U) 2.77 2.26 0.019 196
Critical organ bleeding 0.82 1.18 0.007 278
Bleeding causing death 0.24 0.48 0.003 417
Hemorrhagic stroke 0.26 0.44 0.024 556
Intracranial hemorrhage 0.49 0.74 0.019 400
  1. NNH, number needed to harm; NNT, number needed to treat. Data from Mahaffey KW. AHA Scientific Sessions 2010.